CYP3A5

CYP3A5 encodes a member of the cytochrome P450 superfamily of enzymes. Like most of the cytochrome P450, the CYP3A5 is expressed in the prostate and the liver.{{cite web|title=P08684-CP3A4_Human|url=https://www.uniprot.org/uniprot/P08684|website=UniProt|access-date=November 11, 2014}} It is also expressed in epithelium of the small intestine and large intestine for uptake and in small amounts in the bile duct, nasal mucosa, kidney, adrenal cortex, epithelium of the gastric mucosa with intestinal metaplasia, gallbladder, intercalated ducts of the pancreas, chief cells of the parathyroid and the corpus luteum of the ovary (at protein level).

The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. The enzyme metabolizes drugs such as nifedipine and cyclosporine as well as the steroid hormones testosterone, progesterone and androstenedione. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. This cluster includes a pseudogene, CYP3A5P1, which is very similar to CYP3A5. This similarity has caused some difficulty in determining whether cloned sequences represent the gene or the pseudogene.{{cite web | title = Entrez Gene: CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=1577}}

CYP3A4/3A5 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Immunoblot analysis of liver microsomes showed that CYP3A5 is expressed as a 52.5-kD protein, whereas CYP3A4 migrates as a 52.0-kD protein.{{cite web|title=CYTOCHROME P450, SUBFAMILY IIIA, POLYPEPTIDE 5; CYP3A5|url=http://www.omim.org/entry/605325|website=OMIM|access-date=November 11, 2014}} The human CYP3A subfamily, CYP3A4, CYP3A5, CYP3A7 and CYP3A43, is one of the most versatile of the biotransformation systems that facilitate the elimination of drugs (37% of the 200 most frequently prescribed drugs in the U.S.{{cite journal | vauthors = Zanger UM, Turpeinen M, Klein K, Schwab M | title = Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation | journal = Analytical and Bioanalytical Chemistry | volume = 392 | issue = 6 | pages = 1093–108 | year = 2008 | pmid = 18695978 | doi = 10.1007/s00216-008-2291-6 | s2cid = 33827704 }}).

CYP3A4 and CYP3A5 together account for approximately 30% of hepatic cytochrome P450, and approximately half of medications that are oxidatively metabolized by P450 are CYP3A substrates.{{cite web|title=CYP3A5|url=http://www.pharmgkb.org/gene/PA131?tabType=tabVip|website=PharmGKB|access-date=November 11, 2014}} Both CYP3A4 and CYP3A5 are expressed in liver and intestine, with CYP3A5 being the predominant form expressed in extrahepatic tissues.

The (wild-type) CYP3A enzymes have traditionally been thought of as functionally redundant, distinguishable mostly by expression patterns. Since CYP3A5 is almost always expressed at significantly lower levels than CYP3A4, an understanding of its clinical significance was limited. Most studies suggesting any non-overlapping metabolic functions apart from CYP3A4 were limited to small differences in metabolites produced from drugs which themselves were still substrates of CYP3A4.{{cite journal | vauthors = Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD | title = Selective metabolism of vincristine in vitro by CYP3A5 | journal = Drug Metabolism and Disposition | volume = 34 | issue = 8 | pages = 1317–1327 | date = August 2006 | pmid = 16679390 | doi = 10.1124/dmd.106.009902 | s2cid = 1225633 }} However, in 2016 it was found that CYP3A5 mediated acquired drug resistance in pancreatic ductal adenocarcinoma, a type of pancreatic cancer.{{cite journal | vauthors = Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR | display-authors = 6 | title = CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma | journal = Nature Medicine | volume = 22 | issue = 3 | pages = 278–287 | date = March 2016 | pmid = 26855150 | pmc = 4780258 | doi = 10.1038/nm.4038 }} This not only showed a context of selective CYP3A5 expression, but also demonstrated a therapeutic need for selective CYP3A5 inhibition and hinted that its metabolic role was not completely redundant with CYP3A4. Indeed, chemical tools would soon after be developed which could demonstrate and probe the selective CYP3A5 metabolic activity.

In 2020, Wright et al. reported the first CYP3A5-selective inhibitor clobetasol propionate.{{cite journal | vauthors = Wright WC, Chenge J, Wang J, Girvan HM, Yang L, Chai SC, Huber AD, Wu J, Oladimeji PO, Munro AW, Chen T | display-authors = 6 | title = Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5 | journal = Journal of Medicinal Chemistry | volume = 63 | issue = 3 | pages = 1415–1433 | date = February 2020 | pmid = 31965799 | pmc = 7087482 | doi = 10.1021/acs.jmedchem.9b02067 }} The study demonstrated a strong inhibition of CYP3A5 and showed its high selectivity over other CYP3A enzymes including CYP3A4. It was proposed that clobetasol propionate differentially occupied the binding site of CYP3A5 compared to CYP3A4 (which would later become validated with subsequent studies).{{cite journal | vauthors = Wang J, Buchman CD, Seetharaman J, Miller DJ, Huber AD, Wu J, Chai SC, Garcia-Maldonado E, Wright WC, Chenge J, Chen T | display-authors = 6 | title = Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5 | journal = Journal of the American Chemical Society | volume = 143 | issue = 44 | pages = 18467–18480 | date = November 2021 | pmid = 34648292 | pmc = 8594567 | doi = 10.1021/jacs.1c07066 }}

The CYP3A5 gene has several functional variants, which vary depending on ethnicity. The CYP3A5*1 allele is associated with a normal metabolization of medication. It is most common among individuals native to Sub-Equatorial Africa, though the mutation also occurs at low frequencies in other populations. The CYP3A5*3 allele is linked with a poor metabolization of medication. It is near fixation in Europe, and is likewise found at high frequencies in West Asia and Central Asia, as well as among Afro-Asiatic (Hamitic-Semitic) speaking populations in North Africa and the Horn of Africa. Additionally, the mutation occurs at moderate-to-high frequencies in South Asia, Southeast Asia and East Asia, and at low frequencies in Sub-Equatorial Africa.{{cite journal | vauthors = Valente C, Alvarez L, Marks SJ, Lopez-Parra AM, Parson W, Oosthuizen O, Oosthuizen E, Amorim A, Capelli C, Arroyo-Pardo E, Gusmão L, Prata MJ | title = Exploring the relationship between lifestyles, diets and genetic adaptations in humans | journal = BMC Genetics | volume = 16 | issue = 55 | pages = 55 | date = 28 May 2015 | pmid = 26018448 | doi = 10.1186/s12863-015-0212-1 | pmc=4445807 | doi-access = free }}{{cite web| vauthors = Bains RK |title=Molecular diversity and population structure at the CYP3A5 gene in Africa |url= http://discovery.ucl.ac.uk/1356293/7/1356293_R%20Bains%20ELECTRONIC%20VERSION%20thesis%20-%20post%20viva.pdf |publisher=University College London|access-date=13 June 2016}}

Global distribution of the CYP3A5 alleles:

{{IrinotecanPathway_WP229|highlight=CYP3A5}}

• Cytochrome P450

{{reflist}}

{{refbegin | 2}}

• {{cite journal | vauthors = Smith G, Stubbins MJ, Harries LW, Wolf CR | title = Molecular genetics of the human cytochrome P450 monooxygenase superfamily | journal = Xenobiotica | volume = 28 | issue = 12 | pages = 1129–65 | date = December 1998 | pmid = 9890157 | doi = 10.1080/004982598238868 }}
• {{cite journal | vauthors = Lee SJ, Goldstein JA | title = Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests | journal = Pharmacogenomics | volume = 6 | issue = 4 | pages = 357–71 | date = June 2005 | pmid = 16004554 | doi = 10.1517/14622416.6.4.357 | url = https://zenodo.org/record/1236271 }}
• {{cite journal | vauthors = Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV |author10-link=Harry Gelboin |author5-link=Urs A. Meyer | title = Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine | journal = The Journal of Biological Chemistry | volume = 264 | issue = 18 | pages = 10388–95 | date = June 1989 | doi = 10.1016/S0021-9258(18)81632-5 | pmid = 2732228 | doi-access = free }}
• {{cite journal | vauthors = Schuetz JD, Molowa DT, Guzelian PS | title = Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver | journal = Archives of Biochemistry and Biophysics | volume = 274 | issue = 2 | pages = 355–65 | date = November 1989 | pmid = 2802615 | doi = 10.1016/0003-9861(89)90449-9 }}
• {{cite journal | vauthors = Murray GI, Pritchard S, Melvin WT, Burke MD | title = Cytochrome P450 CYP3A5 in the human anterior pituitary gland | journal = FEBS Letters | volume = 364 | issue = 1 | pages = 79–82 | date = May 1995 | pmid = 7750548 | doi = 10.1016/0014-5793(95)00367-I | s2cid = 28711803 | doi-access = free | bibcode = 1995FEBSL.364...79M }}
• {{cite journal | vauthors = Jounaïdi Y, Guzelian PS, Maurel P, Vilarem MJ | title = Sequence of the 5'-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7 | journal = Biochemical and Biophysical Research Communications | volume = 205 | issue = 3 | pages = 1741–7 | date = December 1994 | pmid = 7811260 | doi = 10.1006/bbrc.1994.2870 }}
• {{cite journal | vauthors = McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ, McManus ME | title = Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues | journal = Gut | volume = 36 | issue = 2 | pages = 259–67 | date = February 1995 | pmid = 7883227 | pmc = 1382414 | doi = 10.1136/gut.36.2.259 }}
• {{cite journal | vauthors = Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB | title = CYP3A gene expression in human gut epithelium | journal = Pharmacogenetics | volume = 4 | issue = 5 | pages = 247–59 | date = October 1994 | pmid = 7894497 | doi = 10.1097/00008571-199410000-00003 | url = https://cdr.lib.unc.edu/concern/articles/4x51hm238 }}
• {{cite journal | vauthors = Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB | title = Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test | journal = Drug Metabolism and Disposition | volume = 22 | issue = 6 | pages = 947–55 | year = 1995 | pmid = 7895614 }}
• {{cite journal | vauthors = Schuetz JD, Beach DL, Guzelian PS | title = Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver | journal = Pharmacogenetics | volume = 4 | issue = 1 | pages = 11–20 | date = February 1994 | pmid = 8004129 | doi = 10.1097/00008571-199402000-00002 }}
• {{cite journal | vauthors = Maruyama K, Sugano S | title = Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides | journal = Gene | volume = 138 | issue = 1–2 | pages = 171–4 | date = January 1994 | pmid = 8125298 | doi = 10.1016/0378-1119(94)90802-8 }}
• {{cite journal | vauthors = Schuetz JD, Schuetz EG, Thottassery JV, Guzelian PS, Strom S, Sun D | title = Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells | journal = Molecular Pharmacology | volume = 49 | issue = 1 | pages = 63–72 | date = January 1996 | pmid = 8569713 }}
• {{cite journal | vauthors = Jounaïdi Y, Hyrailles V, Gervot L, Maurel P | title = Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? | journal = Biochemical and Biophysical Research Communications | volume = 221 | issue = 2 | pages = 466–70 | date = April 1996 | pmid = 8619878 | doi = 10.1006/bbrc.1996.0618 | doi-access = free | s2cid = 31275080 }}
• {{cite journal | vauthors = Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Mäenpää J, Edwards RJ, Boobis AR, Raunio H | title = Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta | journal = Biochemical Pharmacology | volume = 51 | issue = 4 | pages = 403–11 | date = February 1996 | pmid = 8619884 | doi = 10.1016/0006-2952(95)02184-1 }}
• {{cite journal | vauthors = Hakkola J, Raunio H, Purkunen R, Pelkonen O, Saarikoski S, Cresteil T, Pasanen M | title = Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy | journal = Biochemical Pharmacology | volume = 52 | issue = 2 | pages = 379–83 | date = July 1996 | pmid = 8694864 | doi = 10.1016/0006-2952(96)00216-X }}
• {{cite journal | vauthors = Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS | title = Expression of cytochromes P450 in human breast tissue and tumors | journal = Drug Metabolism and Disposition | volume = 24 | issue = 8 | pages = 899–905 | date = August 1996 | pmid = 8869826 }}
• {{cite journal | vauthors = Kivistö KT, Bookjans G, Fromm MF, Griese EU, Münzel P, Kroemer HK | title = Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue | journal = British Journal of Clinical Pharmacology | volume = 42 | issue = 3 | pages = 387–9 | date = September 1996 | pmid = 8877031 | pmc = 2042681 | doi = 10.1046/j.1365-2125.1996.42615.x }}
• {{cite journal | vauthors = Janardan SK, Lown KS, Schmiedlin-Ren P, Thummel KE, Watkins PB | title = Selective expression of CYP3A5 and not CYP3A4 in human blood | journal = Pharmacogenetics | volume = 6 | issue = 5 | pages = 379–85 | date = October 1996 | pmid = 8946469 | doi = 10.1097/00008571-199610000-00001 }}
• {{cite journal | vauthors = Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, Boobis AR, Pelkonen O, Raunio H | title = Expression and localization of CYP3A4 and CYP3A5 in human lung | journal = American Journal of Respiratory Cell and Molecular Biology | volume = 16 | issue = 3 | pages = 242–9 | date = March 1997 | pmid = 9070608 | doi = 10.1165/ajrcmb.16.3.9070608 }}
• {{cite journal | vauthors = Hukkanen J, Hakkola J, Anttila S, Piipari R, Karjalainen A, Pelkonen O, Raunio H | title = Detection of mRNA encoding xenobiotic-metabolizing cytochrome P450s in human bronchoalveolar macrophages and peripheral blood lymphocytes | journal = Molecular Carcinogenesis | volume = 20 | issue = 2 | pages = 224–30 | date = October 1997 | pmid = 9364212 | doi = 10.1002/(SICI)1098-2744(199710)20:2<224::AID-MC9>3.0.CO;2-M | s2cid = 25129993 }}

{{refend}}

• {{UCSC gene info|CYP3A5}}

{{Cytochrome P450}}

Category:Cytochrome P450